473 related articles for article (PubMed ID: 17418969)
1. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
3. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
4. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
5. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
[TBL] [Abstract][Full Text] [Related]
6. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
7. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
8. Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT).
Robbins KT; Doweck I; Samant S; Vieira F; Kumar P
Laryngoscope; 2004 Mar; 114(3):411-7. PubMed ID: 15091211
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of low-dose cisplatin-based chemo-irradiation in assessing hearing loss for locally advanced head and neck cancer.
Liao XB; Yan SX
Radiother Oncol; 2009 Feb; 90(2):282, author reply 282-3. PubMed ID: 19042049
[No Abstract] [Full Text] [Related]
10. High-dose intra-arterial cisplatin therapy followed by radiation therapy for advanced squamous cell carcinoma of the head and neck.
Wilson WR; Siegel RS; Harisiadis LA; Davis DO; Nguyen HH; Bank WO
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):809-12. PubMed ID: 11448355
[TBL] [Abstract][Full Text] [Related]
11. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma.
Spring PM; Valentino J; Arnold SM; Sloan D; Kenady D; Kudrimoti M; Haydon RC; Lee C; Given C; Mohiuddin M; Regine WF
Cancer; 2005 Oct; 104(8):1765-71. PubMed ID: 16149090
[TBL] [Abstract][Full Text] [Related]
13. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
Robbins KT; Kumar P; Harris J; McCulloch T; Cmelak A; Sofferman R; Levine P; Weisman R; Wilson W; Weymuller E; Fu K
J Clin Oncol; 2005 Mar; 23(7):1447-54. PubMed ID: 15735120
[TBL] [Abstract][Full Text] [Related]
14. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
[TBL] [Abstract][Full Text] [Related]
15. Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma.
Yu KH; Yu SC; Hui EP; Kam MK; Vlantis AC; Yuen E; Chan AT
Head Neck; 2010 Jul; 32(7):913-20. PubMed ID: 19885925
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients.
Pan CC; Eisbruch A; Lee JS; Snorrason RM; Ten Haken RK; Kileny PR
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1393-402. PubMed ID: 15817342
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck.
Rabbani A; Hinerman RW; Schmalfuss IM; Amdur RJ; Morris CG; Peters KR; Robbins KT; Mendenhall WM
Am J Clin Oncol; 2007 Jun; 30(3):283-6. PubMed ID: 17551306
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.
Zuur CL; Simis YJ; Lamers EA; Hart AA; Dreschler WA; Balm AJ; Rasch CR
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):490-6. PubMed ID: 19135315
[TBL] [Abstract][Full Text] [Related]
20. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures.
Dirix P; Abbeel S; Vanstraelen B; Hermans R; Nuyts S
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):385-92. PubMed ID: 19553033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
